nach oben

PharmacoEconomics

Erschienen in:

01.05.2009 | Review Article

The Cost and Impact of Health Conditions on Presenteeism to Employers

A Review of the Literature

verfasst von: Alyssa B. Schultz, Chin-Yu Chen, Dr Dee W. Edington

Erschienen in: PharmacoEconomics | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Employers are becoming concerned with the costs of presenteeism in addition to the healthcare and absenteeism costs that have traditionally been explored. But what is the true impact of health conditions in terms of on-the-job productivity? This article examines the literature to assess the magnitude of presenteeism costs relative to total costs of a variety of health

Searches of MEDLINE, CINAHL and PubMed were conducted in July 2008, with no starting date limitation, using ‘presenteeism’ or ‘work limitations’ as keywords. Publications on a variety of health conditions were located and included if they assessed the total healthcare and productivity cost of one or more health conditions.

Literature on presenteeism has investigated its link with a large number of health conditions ranging from allergies to irritable bowel syndrome. The cost of presenteeism relative to the total cost varies by condition. In some cases (such as allergies or migraine headaches), the cost of presenteeism is much larger than the direct healthcare cost, while in other cases (such as hypertension or cancer), healthcare is the larger component. Many more studies have examined the impact of pharmaceutical treatment on certain medical conditions and the resulting improvement in on-the-job productivity.

Based on the research reviewed here, health conditions are associated with on-the-job productivity losses and presenteeism is a major component of the total employer cost of those conditions, although the exact dollar amount cannot be determined at this time. Interventions, including the appropriate use of pharmaceutical agents, may be helpful in improving the productivity of employees with certain conditions.

Roberts S. New approach addresses root causes of illnesses. Bus Insur 2005 Feb 28; 39 (9): 11–22

Burton WN, Conti DH, Chen CY, et al. The role of health risk factors and disease on worker productivity. J Occup Environ Med 1999; 41: 863–77PubMedCrossRef

Aronsson G, Gustafsson K, Dallner M. Sick but yet at work: an empirical study of sickness presenteeism. J Epidemiol Community Health 2000; 54: 502–9PubMedCrossRef

Ruez P. Quality and bottom-line can suffer at the hands of the ‘working sick’. Managed Healthcare Executive 2004 Nov; 14 (11): 46–8

Aronsson G, Gustafsson K. Sickness presenteeism: prevalence, attendance-pressure factors, and an outline of a model for research. J Occup Environ Med 2005; 47: 958–66PubMedCrossRef

Hansson M, Bostrom C, Harms-Ringdahl K. Sickness absence and sickness attendance: what people with neck or back pain think. Soc Sci Med 2005; 52: 2183–95

Bekker MH, Croon MA, Bressers B. Childcare involvement, job characteristics, gender and work attitudes as predictors of emotional exhaustion and sickness absence. Work Stress 2005; 19 (3): 221–37CrossRef

Dew K, Keefe V, Small K. ‘Choosing’ to work when sick: workplace presenteeism. Soc Sci Med 2005; 60: 2273–82PubMedCrossRef

Marlowe J. Depression’s surprising toll on worker productivity. Empl Benefits J 2002; 27: 16–21PubMed

10.

Mattke S, Balakrishnan A, Bergamo G, et al. A review of methods to measure health-related productivity loss. Am J Managed Care 2007; 13: 211–7

11.

Burton W, Conti D, Chen C, et al. The impact of allergies and allergy treatment on worker productivity. J Occup Environ Med 2001; 43: 64–71PubMedCrossRef

12.

Lerner D, Amick B, Malspeis S, et al. The Angina-Related Limitations at Work Questionnaire. Qual Life Res 1998; 7: 23–32PubMedCrossRef

13.

Endicott J, Nee J. Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull 1997; 33: 13–6PubMed

14.

van Roijen L, Essink-Bot ML, Koopmanschap MA, et al. Labor and health status in economic evaluation of health care: the Health and Labor Questionnaire. Int J Technol Assess Health Care 1996; 12: 405–15PubMedCrossRef

15.

Kessler R, Barber C, Beck A, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med 2003; 45: 156–74PubMedCrossRef

16.

Kessler RC, Ames M, Hymel PA, et al. Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med 2004; 46: S23–37CrossRef

17.

Kessler RC. HPQ information and survey versions [online]. Available from URL: http://www.hcp.med.harvard.edu/hpq/info.php. Accessed 2008 Oct 25 [Accessed 2009 Mar 30]

18.

Halpern MT, Shikiar R, Rentz AM, et al. Impact of smoking status on workplace absenteeism and productivity. Tob Control 2001; 10 (3): 233–8PubMedCrossRef

19.

Wolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire II. Arth Rheum 2004; 50: 3296–305CrossRef

20.

Kumar RN, Hass SL, Li JZ, et al. Validation of the Health-Related Productivity Questionnaire Diary (HRPQ-D) on a sample of patients with infectious mononucleosis: results from a phase 1 multicenter clinical trial. J Occup Environ Med 2003; 45: 899–907PubMedCrossRef

21.

Stewart WF, Lipton RB, Kolodner K, et al. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000; 88 (1): 41–52PubMedCrossRef

22.

Lerner DJ, Amick III BC, Malspeis S, et al. The Migraine Work and Productivity Loss Questionnaire: concepts and design. Qual Life Res 1999; 8 (8): 699–710PubMedCrossRef

23.

Koopman C, Pelletier KR, Murray JF, et al. Stanford Presenteeism Scale: health status and employee productivity. J Occup Environ Med 2002; 44: 14–20PubMedCrossRef

24.

Lynch W, Riedel J. Measuring employee productivity: a guide to self-assessment tools. Phoenix (AZ): William M. Mercer, Inc. and the Institute for Health and Productivity Management, 2001; 22–43

25.

Turpin RS, Ozminkowski RJ, Sharda CE, et al. Reliability and validity of the Stanford Presenteeism Scale. J Occup Environ Med 2004; 46: 1123–33PubMedCrossRef

26.

Stewart WF, Ricci JA, Chee E, et al. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med 2003; 45: 1234–46PubMedCrossRef

27.

Stewart WF, Ricci JA, Laotta C, et al. Validation of the work and health interview. Pharmacoeconomics 2004; 22: 1127–40PubMedCrossRef

28.

Lerner D, Amick BC, Rogers WH, et al. The Work Limitations Questionnaire. Med Care 2001; 39: 72–85PubMedCrossRef

29.

Lerner D, Amick III BC, Lee JC, et al. Relationship of employee-reported work limitations to work productivity. Med Care 2003; 41: 649–59PubMed

30.

Lerner D, Adler DA, Chang H, et al. The clinical and occupational correlates of work productivity loss among employed patients with depression. J Occup Environ Med 2004; 46: S46–55CrossRef

31.

Lerner D, Reed JL, Massarotti E, et al. The Work Limitations Questionnaire’s validity and reliability among patients with osteoarthritis. J Clin Epidemiol 2002; 55: 197–208PubMedCrossRef

32.

Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213: 102–10PubMedCrossRef

33.

Walker N, Michaud K, Wolfe F. Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol 2005; 32: 980–2

34.

Burton WN, Pransky G, Conti DJ, et al. The association of medical conditions and presenteeism. J Occup Environ Med 2004; 46: S38–45CrossRef

35.

Burton WN, Chen CY, Conti DJ, et al. The association of health risks with on-the-job productivity. J Occup Environ Med 2005; 47: 769–77PubMed

36.

Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharamacoeconomics 1993; 4:353–65CrossRef

37.

Wahlqvist P, Guyatt GH, Armstrong D, et al. Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD): responsiveness to change and English language validation. Pharmacoeconomics 2007; 25 (5): 385–96PubMedCrossRef

38.

Wahlqvist P, Carlsson J, Stalhammar NO, et al. Validity of a Work Productivity and Activity Impairment Questionnaire for patients with symptoms of gastroesophageal reflux disease (WPAI-GERD): results from a cross sectional study. Value Health 2002; 5: 106–13PubMedCrossRef

39.

Reilly MC, Bracco A, Ricci L-F, et al. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire: irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther 2004; 20: 459–67PubMedCrossRef

40.

Reilly M, Tanner A, Meltzer EO. Work, classroom, and activity impairment instruments: validation studies in allergic rhinitis. Clin Drug Invest 1996; 11 (5): 278–88CrossRef

41.

Reilly MC, Lavin PT, Kahler KH, et al. Validation of the dermatology life quality index and the work productivity and activity impairment: chronic hand dermatitis questionnaire in chronic hand dermatitis. J Am Acad Dermatol 2003; 48 (1): 128–30PubMedCrossRef

42.

Goetzel RZ, Ozminkowski RJ, Long SR. Development and reliability analysis of the Work Productivity Short Inventory (WPSI) instrument measuring employee health and productivity. J Occup Environ Med 2003; 45: 743–62PubMedCrossRef

43.

Ozminkowski RJ, Goetzel RZ, Long SR. A validity analysis of the Work Productivity Short Inventory (WPSI) instrument measuring employee health and productivity. J Occup Environ Med 2003; 45: 1183–95PubMedCrossRef

44.

Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics 2004; 22 (3): 165–84PubMedCrossRef

45.

Prasad M, Wahlquist P, Shikiar R, et al. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics 2004; 22 (4): 225–44PubMedCrossRef

46.

Mattke S, Balakrishnan A, Bergamo G, et al. A review of methods to measure health-related productivity loss. Am J Manag Care 2007; 13: 211–7PubMed

47.

Loeppke R, Hymel PA, Lofland JH, et al. Health-related workplace productivity measurement: general and migraine-specific recommendations from the ACOEM expert panel. J Occup Environ Med 2003; 45: 349–59PubMedCrossRef

48.

Burton WN, Chen CY, Schultz AB, et al. Worker productivity loss associated with arthritis. Disease Management 2006; 9 (3): 131–43PubMedCrossRef

49.

National Institutes of Health, Department of Health and Human Services. Disease-specific estimates of direct and indirect costs of illness and NIH support 2000 [online]. Available from URL: http://ospp.od.nih.gov/ecostudies/COIreportweb.htm [Accessed 2008 Jul 14]

50.

Collins JJ, Baase CM, Sharda CE, et al. The assessment of chronic health conditions on work performance, absence and total economic impact for employers. J Occup Environ Med 2005; 47: 547–57PubMedCrossRef

51.

Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med 2004; 46: 398–412PubMedCrossRef

52.

Loeppke R, Taitel M, Richling D, et al. Health and productivity as a business strategy. J Occup Environ Med 2007; 49: 712–21PubMedCrossRef

53.

Burton WN, Morrison A, Wertheimer AI. Pharmaceuticals and worker productivity loss: a critical review of the literature. J Occup Environ Med 2003; 45: 610–21PubMedCrossRef

54.

Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64–9PubMedCrossRef

55.

Hu XU, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159: 813–8PubMedCrossRef

56.

Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med 1997; 39: 320–7PubMedCrossRef

57.

Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646–57PubMedCrossRef

58.

Gerth WC, Sarma S, Hu XH, et al. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model. J Occup Environ Med 2004; 46: 48–54PubMedCrossRef

59.

Davies GM, Santanello N, Gerth W, et al. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia 1999; 19: 497–502PubMedCrossRef

60.

Weaver MB, Mackowiak JI, Solari PG. Triptan therapy impacts health and productivity. J Occup Environ Med 2004; 46: 812–7PubMedCrossRef

61.

Kwong WJ, Taylor FR, Adelman JU. The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. J Occup Environ Med 2005; 47: 1167–73PubMedCrossRef

62.

Landy S, DeRossett SE, Rapoport A, et al. Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes. Med Gen Med 2007; 9: 53

63.

Lofland JH, Gagne JJ, Pizzi LT, et al. Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled multicenter trials. J Occup Environ Med 2007; 49: 252–7PubMedCrossRef

64.

Wang PS, Simon GE, Avorn JA, et al. Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA 2007; 298: 1401–11PubMedCrossRef

65.

Bunn III WB, Pikelny DB, Paralkar S, et al. The burden of allergies – and the capacity of medications to reduce this burden – in a heavy manufacturing environment. J Occup Environ Med 2003; 45: 941–55PubMedCrossRef

66.

Cockburn IM, Bailit AL, Berndt ER, et al. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41: 948–53PubMedCrossRef

67.

Reilly MC, Barghout V, McBurney CR, et al. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2005; 22: 373–80PubMedCrossRef

68.

Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 2005; 100 (9): 1914–22PubMedCrossRef

69.

Mulgrew AT, Ryan CF, Fleetham JA, et al. The impact of obstructive sleep apnea and daytime sleepiness on work limitation. Sleep Med 2007; 9: 42–53PubMedCrossRef

70.

Cyr A, Hagen S. Measurement and quantification of presenteeism. J Occup Environ Med 2007; 49 (12): 1299–300PubMedCrossRef

71.

Lerner D, Allaire SH, Reisine ST. Work disability resulting from chronic health conditions. J Occup Environ Med 2005; 47: 253–64PubMedCrossRef

72.

Pilette PC. Presenteeism in nursing: a clear and present danger to productivity. J Nurs Admin 2005; 35: 300–3CrossRef

73.

Middaugh DJ. Presenteeism: sick and tired at work. Medsurg Nurs 2006; 15: 103–5PubMed

74.

Whitehouse D. Workplace presenteeism: how behavioral professionals can make a difference. Behav Healthcare Tomorrow 2005; 14: 32–5

75.

Sullivan S. Making the business case for health and productivity management. J Occup Environ Med 2004; 46: S56–61CrossRef

76.

Sullivan S. Promoting health and productivity for depressed patients in the workplace. J Managed Care Pharm 2005; 11: S2–5

77.

Lichtenberg FR. Availability of new drugs and Americans’ ability to work. J Occup Environ Med 2005; 47: 373–80PubMedCrossRef

78.

Edington DW. Emerging research: a view from one research center. Am J Health Promot 2001; 15: 341–9PubMedCrossRef

79.

Burton WN, Conti DJ. The real measure of productivity. Bus Health 1999 Nov; 17 (11): 34–6

80.

Davis K, Collins SR, Doty MM, et al. Health and productivity among U.S. workers. Issue Brief (Commonwealth Fund) 2005; 856: 1–10

81.

Koopmanschap M, Burdorf A, Jacob K, et al. Measuring productivity changes in economic evaluation: setting the research agenda. Pharmacoeconomics 2005; 23: 47–54PubMedCrossRef

82.

Pauly MV, Nicholson S, Polsky D, et al. Valuing reductions in on-the-job illness: ‘presenteeism’ from managerial and economic perspectives. Health Economics 2008; 17 (4): 469–85PubMedCrossRef

Titel: The Cost and Impact of Health Conditions on Presenteeism to Employers
A Review of the Literature
verfasst von: Alyssa B. Schultz
Chin-Yu Chen
Dr Dee W. Edington
Publikationsdatum: 01.05.2009
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 5/2009
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200927050-00002

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Cost and Impact of Health Conditions on Presenteeism to Employers

A Review of the Literature

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2009

Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs

Outcomes Associated with Initial versus Later Vancomycin Use in Patients with Complicated Skin and Skin-Structure Infections

Costing Infectious Disease Outbreaks for Economic Evaluation

The Cost of Dementia in Europe

The Future Costs, Risks and Rewards of Drug Development

Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium